Pallas vs Noom: GLP-1 Telehealth Compared

Noom built one of the best-known behavior-change programs in consumer health, and since 2024 its Noom Med arm has sold compounded GLP-1s bundled with that program. Pallas Health comes from the opposite direction: medication-first care with the program layer deliberately optional. Both still offer compounded semaglutide and tirzepatide in 2026 — and their billing structures are strikingly similar — so the real comparison is the program philosophy and a couple of specific numbers.

This is an honest comparison. Pricing on both sides changes often (Noom repriced in July 2026); figures reflect published pricing as of August 2026 — confirm current numbers on both sites before signing up.

The three differences that matter most

1. The program is the product at Noom; it's optional at Pallas. Every Noom Med plan includes the full Noom app — psychology-based lessons, tracking, coaching content. You can't buy the medication without the program, and for many people the curriculum is exactly why they choose Noom. Pallas includes no curriculum: licensed clinician, dose management, unlimited portal messaging, and a free tracking app you can use or ignore.
2. The semaglutide math. Noom's GLP-1Rx (compounded semaglutide, medication included) is $129 for the first four weeks, then $279/month billed as $837 every 12 weeks. Pallas's compounded semaglutide injection is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. Same billing rhythm, roughly $80/month apart in Pallas's favor. On tirzepatide the two are nearly identical: Noom's Plus plan is $149 to start then $299/month ($897 per 12 weeks) — and Pallas's tirzepatide injection is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. Noom's intro month is lower there; the ongoing totals match.
3. What happens if plans change. Per Noom's published refund policy, once a prescription is written, refunds are no longer possible. Pallas refunds in full if a clinician decides treatment isn't right for you, and you can cancel anytime, self-serve, in the portal.

Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.

Quick comparison

What Noom does well

The behavior-change layer is real. Noom's psychology-based curriculum is the most developed in the industry, and pairing it with medication is a coherent thesis: the habits are what remain when a course of medication ends. If you know you want daily lessons, structured tracking, and a program identity, nobody does it at Noom's scale.

An insurance-friendly brand track. For patients who want brand-name Wegovy®, Zepbound®, Ozempic®, or Mounjaro® through insurance, Noom's telehealth track ($39 for the first 30 days, then $99/month, medication billed separately) plus its insurance-checking tools is a structured way to pursue coverage. Pallas is cash-pay and doesn't route insurance.

An established, accredited operation. Noom has operated since 2008, is BBB-accredited with an A+ rating as of August 2026, and carries one of the largest consumer-review bases in the category. It also still offers compounded GLP-1s — including lower-priced low-dose plans — after most large platforms exited.

What Pallas does differently

Medication-first, and cheaper where it counts most. Pallas's compounded semaglutide runs about $80/month below Noom's ongoing rate, with the same everything-included posture: provider care, dose adjustments, unlimited messaging, shipping. One number — $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. — flat at every dose, no curriculum attached.

All 50 states. Noom's compounded plans exclude Alabama, Louisiana, and Mississippi as of August 2026. Pallas serves every state plus DC, asynchronously in most of them.

The stronger safety net. Full refund if a clinician decides treatment isn't right for you — a scenario where Noom's published policy stops offering refunds once the prescription is written. Cancel anytime with no cycle mechanics to time.

A free companion app without a subscription attached. The Pallas companion app (iOS and Android) covers protein, steps, weight trend, and dose reminders — a tool, not a program.

Who should pick which

Noom is probably the better fit if:

• You want the psychology curriculum and structured daily program alongside medication — that's Noom's genuine specialty
• You want to pursue brand-name medication through insurance with a guided track
• You're interested in a lower-priced low-dose plan and a clinician judges it appropriate

Pallas is probably the better fit if:

• You want medication-first care at the lower ongoing semaglutide price
• You live in Alabama, Louisiana, or Mississippi — or just want one platform that covers every state
• You want a full refund if a clinician doesn't prescribe, and cancel-anytime terms
• You prefer async care with anytime provider messaging over a program cadence

Switching between them

Bring your medication name, current dose, and titration history. A new clinician picks up from your current dose — no restart of titration unless you've been off medication for more than four weeks. If you're leaving Noom, note that their refund policy treats written prescriptions as final; time your switch at a cycle boundary. For the clinical side of choosing between molecules, see semaglutide vs tirzepatide.

References

Platform pricing and program details reflect each company's publicly published terms as of August 2026 and change frequently — confirm current numbers on each platform's site before enrolling. The regulatory basis for compounded preparations is summarized by the FDA.

1. Noom. Noom Med plans and pricing and refund policy, as published August 2026 (GLP-1Rx $129 then $279/mo; Plus $149 then $299/mo; new pricing effective July 27, 2026).
2. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. 2025.

Bottom line: Noom sells a program with medication in it — the best behavior-change curriculum in the category, bundled pricing on the same 12-week rhythm Pallas uses, and an insurance-friendly brand track, from an established A+-rated company. Pallas sells the medication care itself: about $80/month less for compounded semaglutide, identical ongoing tirzepatide pricing with a lower Pallas... first month on semaglutide, all 50 states, a full refund if a clinician doesn't prescribe, and cancel-anytime terms. If the curriculum is why you're coming, Noom earns it; if the medication care is the point, Pallas prices it better with stronger exit terms.